Embed Size (px)
Citation preview
May 9, 2017
CURRICULUM VITAE NAME: WILLIAM MARTENS LEE DATE OF BIRTH: January 30, 1942 PLACE OF BIRTH: New York, USA MARITAL STATUS: Married: Elizabeth Maxwell, 1966
Children: Matthew Edmund Caroline
OFFICE ADDRESS: Division of Digestive and Liver Diseases
Department of Internal Medicine University of Texas Southwestern Med School 5323 Harry Hines Blvd Dallas, TX 75390-8887 (214) 645 6111 referrals/clinic (214) 645 8300 FAX (214) 645 6114 internet address: [email protected]
HOME ADDRESS: 3740 Holland Avenue 3D
Dallas TX 75219 214 443 1885 214 616 5313 cell
PRESENT APPOINTMENTS: Professor of Internal Medicine 1990-present University of Texas Southwestern Medical School Holder of the Meredith Mosle Chair in Liver Disease, in honor of William M. Lee, MD 2003-present Professor of Clinical Medicine 2010-2014 The Ohio State University
Lee WM CV, p. 2
EDUCATION: Amherst College, BA cum laude 1963
Columbia University College of Physicians & Surgeons, MD 1967, AOA
PREVIOUS APPOINTMENTS:
Director, Gastroenterology Division 1989-90 Professor of Medicine Medical University of South Carolina
Interim Director, Gastroenterology Division Medical University of South Carolina 1987-88
Associate Professor of Medicine Medical University of South Carolina 1982-89
Assistant Professor of Medicine Medical University of South Carolina 1980-82
Assistant Professor of Clinical Medicine Columbia University College of Physicians and Surgeons 1976-80
Assistant Attending Physician Presbyterian Hospital, New York 1974-80
Associate in Clinical Medicine Columbia University College of Physicians and Surgeons 1974-76
Research Fellow and Honorary Registrar to Dr. Roger Williams Liver Unit Kings College Hospital Medical School London, England 1973-74
Chief Resident (Medicine) Presbyterian Hospital, New York 1972-73
Assistant Resident (Medicine) Presbyterian Hospital, New York 1970-72
Senior Assistant Surgeon St. Elizabeth's Hospital
Lee WM CV, p. 3
U.S. Public Health Service Washington, D.C. 1968-70
Internship (Medicine) Presbyterian Hospital, New York 1967-68
HONORS AND ORGANIZATIONS:
John Woodruff Simpson Fellow Amherst College 1963
Alpha Omega Alpha Columbia University 1966
American Board of Internal Medicine 1973
Eli Lilly Fellow American College of Physicians 1973
American Association for the Study of Liver Disease, Member/Fellow 1976/2014
American College of Physicians, Member 1977
ABIM Gastroenterology Board 1978
American College of Physicians, Fellow 1979
American Gastroenterological Association, Member 1979
American Society for Gastrointestinal Endoscopy, Member 1979
Blaine Brower Traveling Scholar, American College of Physicians 1980
Gastroenterology Research Group 1984
American Federation for Clinical Research 1985
Thomas A. and Shirley W. Roe Award
Lee WM CV, p. 4
Journal of the SC Med Association 1988
American College of Gastroenterology, Fellow 1989
Leon Schiff Lectureship AASLD Annual Mtng 2008
Hyman Zimmerman Memorial Lecture, AASLD Annual Meeting 2013
AASLD Distinguished Clinician Educator/Mentor Award 2014
STANDING COMMITTEES:
Faculty Senate, MUSC 1982-84
Clinical Research Fellow Steering Committee, Chairman 1982-87
Department of Medicine House Staff Recruitment Committee, Chairman 1983-89
Steering Committee, Gastro Section, Southern Medical Association 1983-90 Chairman 1987-88
Editorial Board, J Clin Gastroenterology 1984-91
Institutional Review Board, MUSC 1986-87
American Gastroenterological Association Training and Education Committee 1986-89
Board of Directors, Charleston Interfaith Crisis Ministry (Homeless Shelter) 1986-90
Director, South Carolina Medicaid Liver Transplantation Program 1987-90
Board of Directors, Interfaith Housing Coalition, Dallas 1990-93
Lee WM CV, p. 5
American Ass'n for Study of Liver Disease Publications Committee 1990-93 Chairman, Hepatology subcommittee 1994-1995 Chairman, Publications Committee 1995-97
Board of Directors, Special Camps for Special Kids, Dallas 1991-93
Selected Summaries Contributor, Gastroenterology 1992-7
Medical Staff Executive Committee Zale-Lipshy University Hospital 1992-94
Board of Directors, Hope Cottage Adoption Agency 1993-99
Study Section: NIH Hepatitis C Cooperative Research Centers 1996
American Ass’n for Study of Liver Disease Secretary-Treasurer 1997-2000
Consultant Member, Food and Drug Administration Anti-Infective Advisory Committee 2001-2007
Member, FDA, PhRMA, AASLD ad hoc committee on nomenclature for drug hepatotoxicity 2001-present
Consultant, Food and Drug Administration OTC Product Advisory Committee 2002, 2009
Consultant, White House Office Narcotic Drug Control Policy 2004- Board of Directors, KERA Public Radio Station 2010-16
Lee WM CV, p. 6
PUBLISHED WORKS: PEER-REVIEWED PAPERS
1. Lee WM, Bragg II FE, Jaffe ER. Reduction of methemoglobin in human adult
and cord blood erythrocytes incubated with glucose and inosine. Proc Soc Exp Biol Med 1967;124: 214-217
2. Reed WD, Eddleston ALWF, Mitchell CG, Lee WM, Zuckerman AJ, Williams
R. Exposure and immunity to the hepatitis B virus in a liver unit. Lancet 1974 i, 581-585
3. Lee WM, Reed WD, Mitchell CG, Eddleston ALWF, Zuckerman AJ, Williams
R. Cellular and humoral immunity to the hepatitis B antigen in active chronic hepatitis. Br Med J 1975;1: 705–708
4. Lee WM, Reed WD, Mitchell CG, Dymock IW, Woolf IL, Eddleston ALWF,
Williams R. Cell-mediated immunity to hepatitis B antigen in blood donors with persistent antigenemia. Gut 1975;16: 4116-418
5. Woolf IL, Sheikh NE, Cullens H, Lee WM, Eddleston ALWF, Williams R,
Zuckerman AJ. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J 1976;2:669-671
6. Lee WM, Mitchell CG, Reed WD, Vahrman J, Zuckerman AJ, Eddleston
ALWF, Williams R. Immune responses to hepatitis B surface antigen and to liver-specific lipoprotein in acute type B hepatitis. Gut 1977;18:250-7
7. Shelton LL, Lee WM, Curtis GM, Arnaud P, Galbraith RM. Membrane
antigens in chronic active hepatitis: physicochemical and immunological studies of soluble liver homogenate fractions. Clin Immunol Immunopathol 1983;28:135-141
8. Lee WM, Shelton LL, Galbraith RM. Antibodies to hepatocyte membrane
antigens in chronic liver disease: detection by immuno-flourescence after Bouin's fixation. J Histochem Cytochem 1983;31:1246-49
9. Lee WM, Emerson DL, Werner PAM, Arnaud P, Goldschmidt-Clermont PJ,
Galbraith RM. Decreased serum group-specific component protein levels and complexes with actin in fulminant hepatic necrosis. Hepatology 1985;5:271-275
Lee WM CV, p. 7
10. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Werner PAM, Lee WM. Effects of ligand binding upon measurement of Gc by rocket immunoelectrophoresis: implications for protein determination and for studies of protein/ligand interactions. Electrophoresis 1985;6:155-61
11. Goldschmidt-Clermont PJ, Galbraith RM, Emerson EL, Werner PAM, Nel AE,
Lee WM. Accurate quantitation of native Gc in serum and estimation of endogenous Gc:G-actin complexes by rocket immunoelectrophoresis. Clin Chim Acta 1985;148:173-183
12. Lee WM, Martin KL, Shelton LL, Galbraith RM. Hepatic membrane
antibodies: studies of prevalence and specificity. Clin Exp Immunol 1985;62: 715-23
13. Lee WM, Holley HP, Galbraith GMP. Refractory esophageal candidiasis
associated with a plasma inhibitor of T-lymphocyte function. Am J Med Sci 1986;292:47-52
14. Reynolds FS, Lee WM. Hepatotoxicity following long-term methotrexate.
Southern Med J 1986;79:536-9 15. Mazzetti M, Stefanini GF, Mazzeo V, Baraldini M, Canonica GW, Marini E,
Miglio F, Gasbarrini G, Lee WM. Alterations in helper-specific circulating T-lymphocytes and in the autologous mixed lymphocyte reaction (AMLR) in chronic hepatitis B. Am J Gastro 1987;82:130-4
16. Young WO, Goldschmidt-Clermont PJ, Emerson DL, Lee WM, Jollow DJ,
Galbraith RM. Correlation between extent of liver damage in fulminant hepatic necrosis and complexing of circulating Gc (Vitamin D-binding protein). J Lab Clin Med 1987;110:83-90
17. Lee WM, McLeod L, Martin KL, Galbraith RM. Antibodies to polymerized
human serum albumin in acute and chronic liver disease. Hepatology 1987;7: 906-912
18. Lee WM, Young WO, Goldschmidt-Clermont PJ, Jollow DJ, Emerson DL,
Galbraith RM. Diminished serum Gc (Vitamin D-binding protein) levels and increased Gc:G-actin complexes in a hamster model of fulminant hepatic necrosis. Hepatology 1987;7:825-30
19. Goldschmidt-Clermont PJ, Lee WM, Galbraith RM. Proportion of Gc (Vitamin
D-binding protein) in complexed form: relation to clinical outcome in fulminant hepatic necrosis. Gastroenterology 1988;94:1454-58
Lee WM CV, p. 8
20. Lee WM, Reines HD, Watt GN, Cook JA, Halushka PV, Wise WC, Galbraith RM. Alterations in Gc protein levels and complexing in septic shock. Circ Shock 1989;28:249-55
21. Walpole HE, Lee WM, Walle T, Walle UK, Wilson MJ, Kennedy JW. Rabbit
hepatocytes in primary culture: preparation, viability, and use in studies of propranolol metabolism. Hepatology 1990;11:394-400.
22. Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic.
Southern Med J 1990;83:1047-1049. 23. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin
toxicity. N Engl J Med 1992;326:1335-41. 24. Lee WM, Iverson A, McLeod L, Walpole HE, Arnaud P, Cote PJ, Gerin JL,
Tennant B. Antibodies to polymerized albumin in woodchuck hepatitis virus infection. Viral Immunology 1993;6:13-19.
25. Lee WM. Medical Progress: Acute liver failure. N Engl J Med 1993;329:1862-
72. 26. Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA. Mooren-type
hepatitis C virus-associated corneal ulceration. Ophthalmology 1994;101:736-45
27. Lee WM, Galbraith RM, Watt GH, Hughes RD, Hoffman BJ, Williams R.
Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. Hepatology 1995;21:101-5.
28. Lee WM. Medical Progress: Drug-Induced Hepatotoxicity. N Engl J Med
1995;333:1118-27 29. Karlsberg PL, Lee WM, Casey DL, Cockerell CJ, Cruz PD Jr. Cutaneous
vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia. Arch Dermatol 1995;131:1119-23
30. Thiele DL, DuCharme L, Cunningham MR, Mimms LT, Cuthbert JA, Lee WM,
Combes B. Steroid therapy of chronic hepatitis: Characteristics associated with response in anti-HCV positive and negative patients. Am J Gastroenterol 1996;91:300-08
31. Suhler E, Lin W, Yin H, Lee WM. Decreased plasma gelsolin levels in acute
liver failure, myocardial infarction, septic shock and myonecrosis. Crit Care Med 1997;25:594-8
Lee WM CV, p. 9
32. Wians FH Jr, Lin W, Brown LP, Schiødt FV, Lee WM. Immunonephelometric
quantification of group-specific component protein in patients with acute liver failure. Liver Transplant Surg 1997;3:28-33
33. Schiødt FV, Rochling FJ, Casey DL, Lee WM. Acetaminophen toxicity in an
urban county hospital. N Engl J Med 1997;337:1112-17. 34. Lee WM. Medical Progress: Hepatitis B virus infection. N Engl J Med,
1997;337:1733-45 35. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with
consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997;26:747-54
36. Hamid S, Cruz Jr PD, Lee WM. Urticarial vasculitis caused by hepatitis C
virus infection: response to interferon-alfa therapy. J Amer Acad Dermatol, 1998;39:278-80
37. Lee WM, Reddy KR, Tong M, et al. Early HCV RNA results predict interferon
treatment outcomes in chronic hepatitis C. Hepatology 1998;28:1411-15 38. Pockros PJ, Tong M, Lee WM, van Leeuwen DJ, Keefe EM, Bala K, et al.
Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. J Viral Hepatitis 1998;5:271-6
39. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK,
et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;338:1485-92
40. Schiødt FV, Atillasoy E, Shakil O, Lee WM, et al. Etiology and outcome for
295 patients with acute liver failure in the United States. Liver Transplant Surg, 1999;5:29-34.
41. Dahl B, Schiødt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin
is reduced in trauma patients. Shock 1999;12:102-04 42. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al.
Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-793.
43. Erukhimov JA, Tang Z-L, Johnson BA, Donahoe MP, Razzack JA, Gibson
KF, Lee WM, Wasserloos KJ, Watkins SA, Pitt BR. Actin-containing sera from
Lee WM CV, p. 10
patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Resp Crit Care Med 2000;162:288-94.
44. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R,
Fried MW, Purdum PP III, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
45. Teo EK, Ostapowicz GA, Hussain M, Lee WM, Fontana RJ, Lok ASF and US
ALF Study Group. Hepatitis B infection in patients with acute liver failure in the United States. Hepatology 2001; 33:972-76
46. Malik AH, Kumar KS, Malet PF, Ostapowicz G, Adams G, Wood M,
Yarbrough K,Jones A, Lee WM. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin,in chronic hepatitis C patients who have not responded to standard doseinterferon. Aliment Pharmacol Ther 2002;16:381-6.
47. Schiødt FV, Lee WM, Bondesen S, Ott P, Christensen E. Influence of acute
and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment Pharmacol Ther 2002;16:707-715.
48. McHutchison JG, Manns MP, Patel K, Poynard T, Lindsay KL, Christian Trepo
C, Dienstag J, Lee WM, et al. Adherence to combination therapy enhances sustained response in patients with chronic hepatitis C infection. Gastroenterology 2002;123:1061-69.
49. Ostapowicz GA, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SBH,
Lee WM, et al., Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:945-54.
50. Dahl B, Schiødt FV, Ott P, Wians F, Lee WM, Balko J, O'Keefe GE. Plasma
concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit Care Med 2003;31:152-55.
51. Schiødt FV, Davern TJ, Shakil OA, McGuire B, Samuel G, Lee WM. Viral
hepatitis-related acute liver failure. Am J Gastroenterol 2003;98:448-453. 52. Schiodt FV, Balko J, Schilsky MC, Harrison EH, Thornton A, Lee WM and the
ALFSG. Thrombopoietin in acute liver failure. Hepatology 2003;37:558-61. 53. Lee WM. Medical Progress: Drug-Induced Hepatotoxicity. N Engl J Med
2003;349:474-85.
Lee WM CV, p. 11
54. Umemura T, Tanaka E, Ostapowicz G, Lee WM, Heringlake S, Manns MP,
Tassopoulos NC, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, aplastic anemia and acute and chronic non-A-E hepatitis. J Inf Dis 2003;188:1545-52.
55. Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, Lee WM,
Blei AT and the Acute Liver Failure Study Group. Infection and the progression to deep hepatic encephalopathy in early fulminant hepatic failure. Gastroenterology 2003; 125:755-764.
56. Rothenbach PA, Dahl B, Schwartz JJ, O’Keefe GE, Yamamoto M, Lee WM,
Horton JW, Yin HL, Turnage RH. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 2004; 96: 25 - 31.
57. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al.,
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
58. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson
GT, Lok AS, Morgan TM, Bonkovsky HL, Lee WM, Diengstag JL, Ghany MG, Goodman AD, Everhart JE and the HALT-C Trial Group Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed previous treatment. Gastroenterology 2004;126:1015-23.
59. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et
al., Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. Contr Clin Trials 2004;25:472-92.
60. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, Davern TJ,
Lee WM, Lok AS-F, and the Acute Liver Failure Group. Clinical outcome and virological characteristics of hepatitis B related acute liver failure in the United States. J Viral Hep 2005;12:192-8.
61. Polson J, Lee WM. AASLD Position Paper: Acute Liver Failure. Hepatology
2005,41:1179-97. 62. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S. Hepatic
findings in long-term clinical trials of ximelagatran. Drug Safety 2005; 28:351-70.
Lee WM CV, p. 12
63. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR and The HALT-C Trial Group. Comparison of amplification enzymes for hepatitis C virus quasispecies analysis. Virol J 2005;2:41-6.
64. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK,
Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-92.
65. Lee WM, Polson JE, Carney DS, Sahin B, Gale M, Jr. Reemergence of
hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: Evidence for an occult viral reservoir. J Infect Dis 2005;192:1088-92.
66. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL,
Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM and the HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatology 2005;43:434-41.
67. Schiodt FV, Rossaro L, Stravitz RT, Shakil OA, Chung RT, Lee WM, and the
ALF Study Group. Gc-globulin and prognosis in acute liver failure. Liver Transplant 2005;11:1223-27.
68. Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, Han S,
Harrison ME, Stravitz TR, Muñoz S, Brown R, Lee WM, Blei AT. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005;11:1581-9.
69. Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due
to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005;50:1785-90. 70. Larson AM, Fontana RJ, Davern TJ, Polson J, Lalani EK, Hynan LS, Reisch
JS, Shakil OA, Schiødt FV, Ostapowicz GA, Lee WM and the ALFSG. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005:42:1367-72.
71. Davern II, TJ, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ,
Lalani EK, Munoz S, Shakil AO, Lee WM and the ALFSG. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006:130:687-94.
Lee WM CV, p. 13
72. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, DiBisceglie AM, Lee WM, Dienstag HL, Ghany MG, Gretch DR and the HALTC Trial Group. HCV RNA detection by TMA during the hepatitis C antiviral longterm treatment against cirrhosis (HALT-C) trial. Hepatology 2006;44:360-67.
73. James LP, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, Squires
RH and the Pediatric Acute Liver Failure Study Group. Detection of acetaminophen-protein adducts in children with acute liver failure of indeterminate cause. Pediatrics 2006;118:676-681.
74. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman
ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial. Hepatology 2006;44:1675-84.
75. Schiodt FV, Ostapowicz GA, Murray N, Satyanarana R, Zaman A, Munoz S.
Lee WM and the Acute Liver Failure Study Group. Alpha fetoprotein and prognosis in acute liver failure. Liver Transpl 2006;12:1776-81.
76. Rutherford A, Davern T, Hay JE, Murray NG, Hassanein T, Lee WM, Chung
RT. High body mass index predicts poor outcome in acute liver failure. Clin Gastroenterol Hepatol 2006,4:1544-49.
77. Lee WM, Brown KE, Young NS, Dawson GJ, Schlauder GG, Gutierrez RA,
Fontana R, Rossaro L, Davern T, Lalani E and the Acute Liver Failure Study Group. Brief Report: No evidence for hepatitis E or parvovirus B19 Infection in patients with acute liver failure. Dig Dis Sci 2006 51:1712-5.
78. Jain MK, Parekh NK, Hester J, Lee WM. Aminotransferase elevation in
HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS. 2006;20:817-822.
79. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT,
Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR; HALT-C Trial Group. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006;44:360-7.
80. Schappert J, Wians FH Jr, Schiff E, Smalley D, Gambardella R, Lee WM, Wu
J, Keiser P, Peterson D, De Medina M, Baker L, Preisel-Simmons B. Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay. Clin Chim Acta. 2006;372:158-66.
Lee WM CV, p. 14
81. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman
ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial. Hepatology 2006;44(:1675-84.
82. Averill J, Lee WM, Karandikar N. Differential dysfunction in dendritic cell
subsets during chronic hepatitis C infection. Clin Immunol 2007;123:40-49. 83. Taylor RM, Davern TJ, Munoz S, Han SH, McGuire B, Larson AM, Hynan L,
Lee WM. Fontana RJ and the ALFSG. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology 2006;44:1589-97.
84. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS,
Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DTY, Weinman SA, Lemon SM, Gale M. Viral and therapeutic control of IFN-ß promoter stimulator 1 during hepatitis C virus infection. PNAS 2006;103: 6001-15.
85. Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar
N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV co-infected patients: factors associated with response. J Viral Hep 2007;14:176-82.
86. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL,
Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR and the HALTC Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-11
87. Lok ASF, Everhart JS, Chung RT, Padmanabhan L, Greenson JK, Shiffman
ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM and the HALTC Trial Group. Hepatic steatosis in hepatitis C: Comparison of diabetic and nondiabetic patients in the HALTC Trial. Gastroenterol Hepatol 2007;5:245-54
88. Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care
providers appropriately manage hepatitis B in co-infected patients treated with anti-retroviral therapy? Clin Infect Dis 2007 2007;44:996-1000
Lee WM CV, p. 15
89. Parekh NK, Hynan LS, De Lemos J, Lee WM and the ALF Study Group. Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of the acute liver failure? Hepatology 2007;45:1489-95
90. Stravitz RT, Kramer AH, Davern T, Shaikh AOS, Caldwell SH, Mehta RL, Blei
AT, Fontana RJ, McGuire BM, Lee WM and the Acute Liver Failure Study Group. Intensive care of patients with acute liver failure: Recommendations of the Acute Liver Failure Study Group. Crit Care Med 2007;35:2498-2508
91. Schiodt FV, Bangert K, Shakil AO, McCashland T, Murray N, Hay JE, Lee
WM and the Acute Liver Failure Study Group. Predictive value of actin-free Gc globulin in acute liver failure. Liver Transplant 2007;13:1324-29
92. Leung PSC, Davis PA, Park O, Miyakawa H, Norman G, Rossaro L, Lee WM,
Gershwin ME and the Acute Liver Failure Study Group. Anti-mitochondrial autoantibodies in acute liver failure. Hepatology 2007;46:1436-42
93. Møller HJ, Grønbaek H, Schiødt FV, Holland-Fischer P, Schilsky M, Munoz S,
Hassanein T, Lee WM and the ALFSG. Soluble CD 163 from macrophages predicts mortality in acute liver failure. J Hepatol 2007;47:671-6
94. Pillai V. Lee WM, Thiele D, Karandikar N. Clinical responders to interferon
treatment for chronic hepatitis C show CD4+ and CD8+ responses. J Viral Hep 2007;14:318-29
95. Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, Vardhineni K,
Lee WM. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med 2007;8:491-7
96. Rutherford AE, Hynan LS, Borges CBS, Forcione DG, Blackard JT, Lin W,
Gorman AJ, Shaikh OS, Reuben A, Harrison E, Reddy KR, Lee WM, Chung RT. Serum apoptosis markers in acute liver failure: A pilot study. Clin Gastroenterol Hepatol 2007;5:1477-83
97. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL,
Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT‐C Trial Group. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47:605-12
98. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute Liver
Failure: Summary of a Workshop. Hepatology 2008;47:1401-15
Lee WM CV, p. 16
99. Polson J, Wians Jr FH, Orsulak P, Fuller D, Murray NG, Koff JM, Khan AI, Balko JA, Hynan LS, Lee WM and the ALFSG. False positive acetaminophen concentrations in patients with liver injury. Clin Chim Acta 2008;391:24-30
100. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JL,
Wright EC, Lee WM, et al. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon: the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial. New Engl J Med 2008;359:2429-41
101. Levitsky J, Thadareddy A, Lakeman FD, Whitley RJ, Luby JP, Lee WM.
Fontana RJ, Blei AT, Ison MG. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transplant 2008;14:1498-1504.
102. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr,
Lee WM, Schilsky M. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology 2008;48:1167-74
103. Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D,
Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O’Brien TR, and the HALT-C Trial Group. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. J Hepatology 2008;49:548-56
104. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson
GT, Lok ASF, Bonkovsky HL, Lee WM et al. Blunted cytopenias and weight loss: New correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastro Hepatol 2008;6:234-41
105. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch
DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok ASF, Dienstag JL, Ghany MG, Curto TM, and the HALT-C Trial Group. Interpretation of positive TMA test results from PCR-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008;
106. Schiff E, Simsek H, Lee WM, Chao, Y-C, Sette H, Janssen HL et al.
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-83
107. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM and Seeff
L. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-57
Lee WM CV, p. 17
108. Lok ASF, Seeff LB, Morgan TR, DiBisceglie AM, Sterling RK, Curto TM, Lindsay KM, Lee WM. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-148
109. Cote GC, Gottstein JH, Daud A, Lee WM, Blei AT and the ALFSG. The
Role of etiology in the hyperamylasemia of acute liver failure. Am J Gastroenterol 2009;104:592–97
110. James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA,
Davern TJ, Lee WM. Pharmacokinetics of acetaminophen protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos 2009;37:1-6
111. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM,
Davern TL III, Murray NG, McCashland T, Reisch J, Robuck PR and the ALFSG. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137:856-864
112. McHutchinson JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone
J, Nyberg LM, Lee WM, et al. Peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for the treatment of chronic hepatitis C genotype 1 infection. N Engl J Med 2009;369:580-593
113. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM,
Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009;49:1847-58
114. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman
ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009;50:1360-9
115. Lok ASF, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs JC,
Greenson JK, Sterling RK, Lindsay KL, Lee WM and the HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the HALT-C Trial. Hepatology 2009;49:1828-37
Lee WM CV, p. 18
116. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F et al. Merimepodib, pegylated interferon, and ribavirin in genotype-1 chronic hepatitis C pegylated interferon and ribavirin non-responders: a randomized study. Hepatology 2009;50:1719-26
117. Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis 2009;200: 866-76
118. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J,
Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
119. Forde KA, Reddy KR, Troxel AB, Sanders CM, Lee WM; Acute Liver
Failure Study Group. Racial and ethnic differences in presentation, etiology, and outcomes of acute liver failure in the United States. Clin Gastroenterol Hepatol 2009;7:1121-6
120. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM,
Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:498-502
121. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM,
Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137:1986-94
122. Schiødt FV, Chung RT, Schilsky ML, Hay JE, Christensen E, Lee WM and
the Acute Liver Failure Study Group. Outcome of acute liver failure in the elderly. Liver Transpl 2009 15:1481-7
123. Yuan HJ, Jain MK, Snow KK, Gale Jr, M, Lee WM and the HALT-C Trial
Group. Evolution of hepatitis C virus NS5A region in breakthrough patients during interferon and ribavirin therapy. J Viral Hep 2010;17:208-216
124. Ghany MG, Lok ASF, Everhart JE, Everson GT, Lee WM, Curto TM,
Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL,
Lee WM CV, p. 19
Morishima C, Morgan TR, Dienstag JL and the HALT-C Trial Group. Predicting clinical and histological outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136-46
125. Getachew Y, James L, Lee WM, Thiele DL, Miller BC. Biochem
Pharmacol. Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. Biochem Pharmacol 2010; 79:1363-71
126. Li J, Zhu X, Liu F, Cai P, Sanders C, Lee WM, Uetrecht J. Cytokine and
autoantibody patterns in acute liver failure. J Immunotoxicol 2010;7:157-164 127. Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ
2nd, Hayashi P, Lee WM, Seeff LB. Hepatotoxicity Due to Hydroxycut: A Case Series. Am J Gastroenterol 2010;105:1561-6
128. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al.,
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C Trial. Clin Gastroenterol Hepatol 2010;8:977-83
129. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt
CM, Freston JW. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Safety 2010;33:503-22
130. Morgan TR, Ghany MG. Kim HY. Snow KK, Shiffman ML, De Santo JL,
Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-44
131. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE et al. Factors that
determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010; 138:2321-32
132. Seremba E, Ocama P, Opio CK, Kagimu M, Yuan HJ, Attar N, Thomas
DL, Lee WM. Validity of rapid strip assay test (RSA) for detecting HBsAg among hospitalized patients in Uganda. J Med Virol 2010:82:1334-40
133. Li J, Zhu X, Liu F, Cai P, Sanders C, Lee WM, Uetrecht J. Cytokine and
autoantibody patterns in acute liver failure. J Immunotoxicol 2010;7:157-64. 134. Seremba E, Ocama P, Opio CK, Kagimu M, Thomas DL, Yuan HJ, Attar
N, Lee WM. Poor performance of hepatitis C antibody tests in hospitalized
Lee WM CV, p. 20
individuals in Uganda. J Med Virol 2010; 82:1371-78 135. Gregory B, Larson AM, Reisch J, Lee WM. Acetaminophen dose does not
predict outcome in acetaminophen-induced acute liver failure. J Invest Med 2010;58:707-10
136. Reuben A, Koch DG, Lee WM and the Acute Liver Failure Study Group.
Drug-Induced Acute Liver Failure: Results of a United States multicenter, prospective study. Hepatology 2010;52:2065-78.
137. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM,
Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA. Albrecht JK, McHutchison JG. IDEAL Study Team. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602-11.
138. Hu KQ. Schiff ER. Kowdley KV. Min AD. Shiffman ML. Lee WM. Goodman
ZD. Dau LO. Peschell KJ. Fagan EA. Flaherty JF. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroenterol 2010;44:510-6.
139. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban
T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.
140. Strnad P, Zhou Q, Hanada S, Lazzeroni LC, Hui B, Zhong P So P, Davern TJ, Lee WM for the Acute Liver Failure Study Group and Omary MB. Ethnic-specific keratin variants predispose to an adverse outcome in acute liver failure. Gastroenterology 2010;139:828-35.
141. Mohutsky MA, Romeike A, Meador V, Lee WM, Fowler J, Francke-Carroll
S. Hepatic drug metabolizing enzyme induction and implications for preclinical and clinical risk assessment. Toxicol Pathol 2010;38:799-809.
142. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL,
Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated,
Lee WM CV, p. 21
histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405. 143. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM,
Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int 2011;5:654-63.
144. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011;53:1100-8
145. Ayers CL, Firan M, Pillai V, Lee WM, Karandikar NJ. Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. Viral Immunol 2011;24:119-29
146. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D; HALT-C Trial Study Group. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol 2011;106:884-93
147. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-9
148. Ajmera V, Xia G, Vaughan G, Forbi J, Ganova-Raeva LM, Khudyakov Y,
Opio CK, Taylor R, Restrep R, Munoz S, Fontana RJ, Lee WM and the ALFSG. What factors determine the severity of hepatitis A related acute liver failure? J Viral Hep 2011;18:e174-8.
149. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM, Acute Liver
Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011;53:567-76
150. Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling
RK, Manns MP, Norman GL, Lee WM and the ALFSG. Autoimmune acute liver failure: Proposed clinical and histological criteria. Hepatology 2011; 53:517-526
Lee WM CV, p. 22
151. Dao DY, Balko J, Attar N, Neak E, Yuan HJ, Lee WM, Jain MK. Hepatitis B virus genotype G: Prevalence and impact in HIV/HBV co-infected patients. J Med Virol 2011;83:1551-8
152. Taylor RM, Tujios S, Jinjuvadia K, Davern T, Shaikh OS, Han S, Chung
RT, Lee WM, Fontana RJ. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig Dis Sci 2012;57:777-85
153. Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, Lok ASF, Word
RA, Lee WM. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum IgM anti-HBc and HBV DNA levels. Hepatology 2012;55:676-684
154. Jain MK, Seremba E, Bhore R, Dao D, Joshi R, Attar N, Yuan HJ, Lee
WM. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. AIDS Patient Care STDS. 2012;26:73-80
155. Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization
of hepatocellular carcinoma surveillance among American patients: A systematic review. J Gen Intern Med 2012;27:861-70.
156. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim
A, Lee WM, Sanyal AJ. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012;56:129-36.
157. Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM and the
ALFSG. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci 2012;57:1349-5.
158. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL,
Lee WM and the HALT-C Trial Group. Antigen-specific lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hep 2012;19:404-409.
159. Chung RY, Stravitz, RT, Fontana RJ, Schiodt FV, Mehal W, Reddy R, Lee
WM. Pathogenesis of Liver Injury in Acute Liver Failure: Meeting Summary. Gastroenterology 2012;143:e1-7.
160. Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. A single
nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. J Med Virol. 2012; 84: 1913-20.
Lee WM CV, p. 23
161. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D,
Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB; on behalf of the Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, the Spanish DILI Registry, and the International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012;22:784-795
162. Carpenter TO, Zhang JH, Parra E, Ellis BK, Simpson C, Lee WM, Balko J,
Fu L, Wong BY, Cole DE. Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. J Bone Miner Res 2012 28:213-22.
163. Rutherford A, King LY, Hynan LS, Vedvyas C, Lin W, Lee WM, Chung RT;
ALF Study Group. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 2012;143:1237-43.
164. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M,
Lee WM, Marrero JA, Tiro JA. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res. 2012;5:1124-30.
165. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC; HALT-C Trial Group. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat 2012;19:404-13.
166. Jain MK, Seremba E, Bhore R, Dao D, Joshi R, Attar N, Yuan HJ, Lee WM. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. AIDS Patient Care STDS 2012;26:73-80.
167. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL,
Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC and HALT-C Trial. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat 2012;19:404-13.
168. Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan HJ, Pearlman BL, Vaughan
G, Forbi JC, Xia GL, Khudyakov YE. Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. In Silico Biol 2012;11:213-24.
169. Grant LM, Kleiner DE, Conjeevaram HS, Vuppalanchi R, Lee WM. Clinical
and histological features of hepatotoxicity due to temozolomide: a case
Lee WM CV, p. 24
series. Dig Dis Sci, 2013;58:1415-21 170. Chen EY, Baum K, Collins W, Love A, Merz M, Olafsson S, Bjornsson R,
Lee WM. Hepatitis E masquerading as drug-induced liver injury. Hepatology 2012;56:2420-23.
171. Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM. A small
percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol 2013;epub ahead of print.
172. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok
AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108::425-32
173. Chen EY, Lee WM, Hynan LS, Singal AG. A survey of hepatitis C
treatment clinical practice patterns using the newly approved protease inhibitors. J Clin Gastroenterol 2013;47:800-6
174. Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan
SC, Greenblatt DJ, Lee WM, and the ALFSG. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042>G (rs 8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A Exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther 2013;345:297-307.
175. Singh S, Hynan LS, Lee WM and the ALFSG. Improvements in hepatic
serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013;58:1397-1402.
176. North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R,
Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013;35:122-8.
177. Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan HJ, Pearlman BL, Vaughan
G, Forbi JC, Xia GL, Khudyakov YE. Coordinated evolution among hepatitis C genomic sites is coupled with host factors and resistance to interferon. In Silico Biol 2011-12;11:213-24.
178. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. Pegylated
interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob Agents Chemother 2013;57:1115-20.
Lee WM CV, p. 25
179. Rangnekar AS, Ellerbe C, Durkalski V, McGuire B, Lee WM, Fontana RJ.
Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. Liver Transpl 2013;19:991-1000.
180. Stravitz RT, Sanyal AJ, Reisch J, Bajaj JS, Mirshahi F, Cheng J, Lee WM and the Acute Liver Failure Study Group. Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver Int 2013;33:1324-31.
181. Opio CK, Seremba E, Ocama P, Lalitha R, Kagimu M, Lee WM. Diagnosis of alcohol misuse and alcoholic liver disease among patients in the medical emergency admission service of a large urban hospital in Sub-Saharan Africa; a cross sectional study. Pan Afr Med J 2013;15:23-30.
182. Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM,
Brown RS Jr; the Acute Liver Failure Study Group. Steroid use in acute liver failure. Hepatology 2014;59:612-21.
183. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins
PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology 2014;59:661-70.
184. Metushi IG, Sanders C, Lee WM, Uetrecht J. Detection of Anti-Isoniazid
and Anti-CYP Antibodies in Patients with Isoniazid-Induced Liver Failure. Hepatology 2014;59:1084-93.
185. Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani
N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, Stolz A, Talwalkar J, Davern T, Saha D, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 2013;27;8:e81974.
186. Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM; Acute
Liver Failure Study Group. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos 2014;42:28-32.
187. Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders
C, Lee WM; for the US Acute Liver Failure Study Group. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute
Lee WM CV, p. 26
liver failure: A retrospective cohort study. Clin Gastroenterol Hepatol. 2014;12:1942-9.
188. Metushi IG, Lee WM, Uetrecht J.IgG3 is the dominant subtype of anti-
Isoniazid and anti-P450 antibodies in patients with isoniazid-induced liver failure. Chem Res Toxicol 2014;27:738-40.
189. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB,
Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwalkar JA; on behalf of the DILIN network. Idiosyncratic Drug Induced Liver Injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014 Mar 26 epub
190. Mellinger JL, Rossaro L, Naugler WE, Nadig SN, Appelman H, Lee WM,
Fontana RJ. Epstein-Barr virus (EBV) related acute liver failure: A case series from the US Acute Liver Failure Study Group. Dig Dis Sci. 2014;59:1630-7.
191. Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG,
Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. Clin Infect Dis 2014;58:960-9.
192. Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM;
U.S. Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: A retrospective cohort study. Crit Care Med 2014;42:1157-67.
193. Fontana RJ, Ellerbe C, Durkalski VE, Rangnekar A, Reddy KR, Stravitz T,
McGuire B, Davern T, Reuben A, Liou I, Fix O, Ganger DR, Chung RT, Schilsky M, Han S, Hynan LS, Sanders C, Lee WM; The US Acute Liver Failure Study Group. Two-year outcomes in initial survivors with acute liver failure: Results from a prospective, multicenter study. Liver Int 2015;35:370-80.
194. Tujios SR, Hynan LS, Vazquez MA, Larson AM, Seremba E, Sanders CM,
Lee WM; Acute Liver Failure Study Group. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13:352-9.
195. McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H; Acute Liver
Failure Study Group. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology 2014;60:1336-45.
Lee WM CV, p. 27
196. Dubin PH, Yuan HJ, Devine RK, Hynan LS, Jain MK, Lee WM; Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol 2014;86:1507-14.
197. Long D, Fix OK, Deng X, Seielstad M, Lauring AS; Acute Liver Failure
Study Group. Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis A virus infection. J Med Virol 2014;86:1661-8.
198. Karvellas CJ, Stravitz RT, Battenhouse H, Lee WM, Schilsky ML; for the
US Acute Liver Failure Study Group. Therapeutic hypothermia in acute liver failure: A multi-center retrospective cohort analysis. Liver Transpl 2015;21:4-12.
199. Rich NE, Sanders C, Hughes RS, Fontana RJ, Stravitz RT, Fix O, Han SH, Naugler WE, Zaman A, Lee WM. Malignant Infiltration of the liver presenting as acute liver failure. Clin Gastroenterol Hepatol 2014;13:1025-8.
200. Woolbright BL, McGill MR, Staggs VS, Winefield RD, Gholami P, Olyaee M, Sharpe MR, Curry SC, Lee WM, Jaeschke H, the Acute Liver Failure Study Group. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci 2014 Sep 19,Epub ahead of print
201. Laursen TL, Sandahl TD, Støy S, Schiødt FV, Lee WM, Vilstrup H, Thiel S, Grønbaek H; US Acute Liver Failure Study Group. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. Liver Int 2014 Sep 9. Epub ahead of print.
202. Zacharias T, Wang W, Dao D, Wojciechowski H, Lee WM, Do S, Singal
AG.HBV Outreach programs significantly increase knowledge and vaccination rates among Asian Pacific Islanders. J Community Health 2014 Dec 5
203. Foureau DM, Walling TL, Maddukuri V, Anderson W, Culbreath K, Kleiner
DE, Ahrens WA, Jacobs C, Watkins PG, Fontana RJ, Chalasani N, Talwalkar J, Lee WM, Stolz A, Serrano J, Bonkovsky HL.Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2014 Nov 23. [Epub ahead of print]
204. Speiser JL, Durkalski VL, Lee WM Random forest classification of
etiologies for an orphan disease. Stat Med 2014;34:887-99. 205. Dubin PH, Sclair SN, Rico R, Boehme AK, Chen EY, Martin P, Lee WM.
Low SVR rates in clinical practice for treating Genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir. Dig Dis Sci 2015;60:272-4.
206. Woolbright BL, McGill MR, Staggs VS, Winefield RD, Gholami P, Olyaee
Lee WM CV, p. 28
M, Sharpe MR, Curry SC, Lee WM, Jaeschke H; Acute Liver Failure Study Group. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci 2014;142:436-44.
207. Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, Shuhart MC, Lau DT, Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS; Hepatitis B Research Network; Hepatitis B Research Network. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol 2015;13:183-92.
208. Zacharias T, Wang W, Dao D, Wojciechowski H, Lee WM, Do S, Singal
AG. HBV outreach programs significantly increase knowledge and vaccination rates among Asian Pacific Islanders. J Community Health 2015;40:619-24.
209. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH; US Drug-Induced Liver Injury Network Investigators. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol. 2015;148:1340-52.
210. Speiser JL, Lee WM, Karvellas CJ; US Acute Liver Failure Study Group. Predicting outcome on admission and post-admission for acetaminophen-induced acute liver failure using classification and regression tree models. PLoS One 2015; April 17 epub.
211. Basta G, Del Turco S, Navarra T, Lee WM; Acute Liver Failure Study Group. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure. Liver Transpl 2015;21:847-54.
212. Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM; Acute Liver Failure Study Group. Plasma osteopontin in acute liver failure. Cytokine 2015 ;73:270-6.
213. Serper M, Wolf MS, Parikh NA, Tillman H, Lee WM, Ganger DR. Risk factors, clinical presentation, and outcomes in overdose with acetaminophen alone or with combination products: Results from the Acute Liver Failure Study Group. J Clin Gastroenterol 2016;50z:85-91.
214. Apica BS, Seremba E, Rule J, Yuan H-J, Lee WM. High prevalence of
occult hepatitis B infection in an African urban population. J Med Virol 2015: Sep 3, epub ahead of print.
Lee WM CV, p. 29
215. Kaur G, Leslie EM, Tillman H, Lee WM, Swanlund DP, Karvellas CJ; US Acute Liver Failure Study Group. Detection of ophthalmic acid in serum from acetaminophen-induced acute liver failure patients is more frequent in non-survivors. PLoS One. 2015 Sep 25.
216. Rule JA, Hynan LS, Attar N, Sanders C, Korzun WJ, Lee WM; Acute Liver
Failure Study Group. Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure. PLoS One. 2015 Sep 22,
217. Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani
N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450-9.
218. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N,et al
Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150:684-695.
219. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of
899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015;148:1340-52.
220. Rosen HR, Biggins SW, Niki T, Gralla J, Hillman H, Hirashima M, Schilsky M, Lee WM; Acute Liver Failure Study Group (ALFSG). Association between plasma level of Galectin-9 and survival of patients with drug-induced acute liver failure. Clin Gastroenterol Hepatol. 2016;14:606-612.
221. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM; Acute Liver Failure Study Group. Thrombocytopenia is associated with multi-organ system failure in patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:613-620.
222. Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, Lee WM; Acute Liver Failure Study Group. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the US. Liver Transpl. 2015;22:505-515.
223. Park J-J, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, et al.
Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 2016;150:684.695.
224. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz R, Lee
WM. Outcomes in adults with acute liver failure (ALF) from 1998-2013: An observational cohort study. Ann Intern Med 2016;164:724-32.
225. Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development
Lee WM CV, p. 30
of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol 2016;14:1199-1206.
226. Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM,
Ganger D. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol 2016;111:958-65.
227. Karvellas CJ, Tillman H, Leung AA, Lee WM, Schilsky ML, Hameed
B, Todd Stravitz R, McGuire BM, Fix OK; United States Acute Liver Failure Study Group. Acute liver injury and acute liver failure from mushroom poisoning in North America. Liver Int 2016 E pub Feb 2
228. Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana
RJ, et al. Drug-Induced Liver Injury Network (DILIN). Liver injury from non-steroidal anti-inflammatory drugs in the United States. Liver Int 201;36:603-9.
229. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M,
Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM; Hepatitis B Research Network. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology 2016;150:684-695.
230. Karvellas CJ, Cardoso FS, Gottfried M, Reddy KR, Hanje AJ, Ganger D,
Lee WM; US Acute Liver Failure Study Group. HBV-associated acute liver failure after immunosuppression and risk of death. Clin Gastroenterol Hepatol 2017;15:113-122.
231. Fontana RJ, Engle RE, Scaglione S, Araya V, Shaikh O, Tillman H, Attar
N, Purcell RH, Lee WM; US Acute Liver Failure Study Group. The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology 2016;64:1870-80.
232. Fix OK, Liou I, Karvellas CJ, Ganger DR, Forde KA, Subramanian RM, Boylan A, Hanje J, Stravitz RT, Lee WM; Acute Liver Failure Study Group. Development and Pilot of a Checklist for Management of Acute Liver Failure in the Intensive Care Unit. PLoS One 2016 May 13;11, Epub
233. Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF; US Acute Liver
Failure Study Group. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology 2016, epub ahead of print, Nov 18,
234. Parekh J, Matei VM, Canas-Coto A, Friedman D, Lee WM; and the Acute
Lee WM CV, p. 31
Liver Failure Study Group. Budd-Chiari syndrome causing acute liver failure: A multicenter case series. Liver Transpl 2016 epub ahead of print Sep 22
235. Roberts DW, Lee WM, Hinson JA, Bai S, Swearingen CJ, Stravitz RT,
Reuben A, Letzig L, Simpson PM, Rule J, Fontana RJ, Ganger D, Reddy KR, Liou I, Fix O, James LP. An immunoassay to rapidly measure acetaminophen protein adducts accurately identifies patients with acute liver injury or failure. Clin Gastroenterol Hepatol 2016 epub ahead of print Sep 15.
236. Davis BC, Tillman H, Chung RT, Stravitz RT, Reddy KR, Fontana RJ,
McGuire B, Davern T, Lee WM. Heat stroke leading to acute liver injury and failure: A case series from the Acute Liver Failure Study Group. Liver Int 2017;January 17, epub
237. Randesi M, Levran O, Correa da Rosa J, Hankins J, Rule J, Kreek MJ,
Lee WM. Association of variants of arginine vasopressin and arginine vasopressin receptor 1A, with severe acetaminophen liver injury. Cell Molec Gastroenterol Hepatol 2017; February, epub ahead of print.
238. Koch DG, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, et
al The natural history of acute liver injury. J Gastroenterol 2017 epub ahead of print. Apr 25
BOOK CHAPTERS, CASE REPORTS, EDITORIALS AND REVIEWS 239. Lee WM. Cellular and humoral immunity in viral hepatitis. Amer J Clin
Path 1976;65:866-9 240. Lee WM, Lebwohl O, Chien S. Hyperviscosity syndrome due to
hyperglobulinemia in chronic active hepatitis. Gastroenterology 1978;74:918-921.
241. Brasitus TA, Gold RP, Kay RH, Magun AM, Lee WM. Intestinal
strongyloidiasis: A case report and review of the literature. Amer J Gastro 1980;73:65-69.
242. Lee WM. Management of massive ascites utilizing ascites reinfusion. J
Clin Gastroenterol 1982;4:87-92. 243. Lee WM. Treating bleeding esophageal varices: Less is more. (Editorial)
J Clin Gastroenterol 1982;4:181-2.
Lee WM CV, p. 32
244. Lee WM, Silva F, Price JB. Gastrin secreting tumor of the duodenum (G-cell apudoma) associated with secondary biliary cirrhosis. Cancer 1982;49:2596-2601.
245. Marsh WH, Cunningham JT, Lee WM. Hepatomegaly and ascites in an
elderly woman with polycythemia vera. J Clin Gastroenterol 1983;5:367-75. 246. Lee WM. Right upper quadrant pain and hepatomegaly in a 28 year old
woman. J Clin Gastroenterol 1984;6:261-6. 247. Loevinger EH, Vujic I, Lee WM, Anderson MC. Hepatic rupture
associated with pregnancy: Diagnosis by CT and angiography with transcatheter embolotherapy. Obstet Gynecol 1985;65:281-4.
248. Lee WM. Pregnancy and Chronic Liver Disease in Gleicher N, ed.
Principles of Medical Therapy in Pregnancy. Plenum Publishing Corp., New York. p. 848-852, 1985
249. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Lee WM.
Evidence of circulating Gc:G-actin complexes in health and disease. Vitamin D; Chemical, biochemical and clinical update (Norman AW, Schaefer K, Grigoleit H-G, and Herraton DV, eds) Walter De Gruyter & Co., Berlin, 1103-1104, 1985
250. Lee WM. The antigens and antibodies of hepatitis B: A Review. J SC
Med Assoc 1986;82:613-619. 251. Lee WM. A hepatologist looks at the irritable bowel syndrome. (Editorial)
J Clin Gastroenterol 1986;8:609-610. 252. Lee WM. Acute and Chronic Viral Hepatitis (chapter) in Conn's Current
Therapy 1988, Robert E. Bakel, ed., W.B. Saunders and Co., Philadelphia, pp. 426-431.
253. Lee WM, Denton WT. Chronic active hepatitis and cirrhosis due to
methyldopa. J SC Med Assoc 1989;85:75-79. 254. Lee WM. Gastroenterology (chapter, p. 165-190) in Critical Care Pearls
1989, S Sahn, J Heffner, eds. Hanley and Belfus Inc. Philadelphia. 255. Wootton FT, Rhodes DF, Lee WM, Fitts CT. Colonic necrosis with
Kayexelate/sorbitol enemas after renal transplantation. Ann Intern Med 1989;111: 947-49.
Lee WM CV, p. 33
256. Lee WM. Metabolic liver diseases. Trans Assn LIMDA. 72: 105-110, 1989 257. Lee WM. Viral Hepatitis (Review of world literature for 1989) Curr Opin Inf
Dis 1990;3:237-245. 258. Krueger K, Hoffman BJ, Lee WM. Hepatic infarction associated with
eclampsia. Am J Gastro 1990;85:588-592. 259. Hoffman BJ, Pate MB, Marsh WH, Lee WM. Cardiomyopathy
unrecognized as a cause of hepatic failure. J Clin Gastroenterol 1990;12:306-309.
260. Lee WM. Hepatitis C (review of the world's literature for 1989-90) Curr
Opin Inf Dis 1990;3:789-795. 261. Lee WM. Hepatitis update: diagnosis, treatment and prevention. Modern
Medicine 1990;58:46-65. 262. Rhodes DF, Lee WM, Wingard JR, Santos GW, Pavy MD, Shaw BW,
Wood RP, Sorrell MF, Markin RS. Orthotopic liver transplantation for graft-versus-host disease following bone marrow transplantation. Gastroenterology 1990;99:537-40.
263. Lee WM. Interferon as treatment for viral hepatitis: a progress report. J SC
Med Assoc 1990;86:440-444. 264. Arterburn JA, Lee WM, Wood RP, Shaw BW, Markin RS. Orthotopic liver
transplantation for cholesteryl ester storage disease. J Clin Gastroenterol 1991;13: 482-6.
265. Lee WM. Pregnancy and Chronic Liver Disease in Gleicher N, ed.
Principles and Practice of Medical Therapy in Pregnancy. p. 976-981, Appleton and Lange Co. East Norwalk. Second Edition, 1992.
266. Lee WM. Pregnancy in patients with chronic liver disease. In Riely CA,
Abell TL, eds. Gastrointestinal and Liver Problems in Pregnancy, Gastro Clin North America, p.889-903, WB Saunders Co. Philadelphia Pa, 1992.
267. Lee WM. Where is the dividing line between autoimmune hepatitis and
hepatitis C? Gastroenterology 1992;102:1814-1815. 268. Foust R, Lee WM. Gastrointestinal vasculitis. In EC LeRoy, Ed. Systemic
Vasculitis, 1992.
Lee WM CV, p. 34
269. Lee WM. Intrahepatic shunts: a new era? Gastroenterology 1992;103: 1357-1358.
270. Lee WM. The silent epidemic of hepatitis C. Gastroenterology 1993;104:
661-663. 271. Lee WM. Should we transplant hepatitis C positive organs?
Gastroenterology 1993;105:300-302. 272. Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA. Mooren's
corneal ulcers and hepatitis C virus infection (letter). N Engl J Med 1993;329:62,
273. Lee WM. Review article. Drug-induced hepatotoxicity. Aliment Pharm
Therapeut 1993;7:477-485,. 274. Lee WM. Acute liver failure: Is anything really effective short of
transplantation? In Difficult Decisions in Gastroenterology, Barkin JS and Rodgers AI. editors, p. 141-146, 1994
275. Lee WM. Gastroenterologists: Get to know gelsolin! Gastroenterology
1994;106:813-814,. 276. Lee WM. Acute liver failure. in Advances in the management of hepatic
disease: clarifying the issues. Am J Med 1994;96:3S-9S,. 277. Lee WM. Total hepatectomy for acute liver failure: don't take out my liver!
Gastroenterology 1994;107: 894-897. 278. Murakami C, Bodenheimer H, Lee WM. Autoimmune thrombocytopenic
purpura during interferon alfa-2b treatment for chronic hepatitis C. Am J Gastroenterol 1994;89:2244-2245.
279. Lee WM. Mapping a strategy for curing hepatitis C. Gastroenterology
1995;108:945-946. 280. Lahoti S, Lee WM. Hepatoxicity of anticholesterol, cardiovascular, and
endocrine drugs and hormonal agents. Gastroenterol Clin North Am 1995;24:907-22.
281. Lee WM. Acute liver failure in Gastroenterology and Hepatology: The
Comprehensive Visual Reference. Vol 1. The Liver eds. Feldman M, Maddrey WC. Current Medicine, Philadelphia, 1996, p. 7.1-7.16.
Lee WM CV, p. 35
282. Lee WM and Maddrey WC. Acute liver failure and transplantation: a symposium, in Liver Transplant Surg 1995;1:176-206.
283. Lee WM. The selling of acetaminophen. Gastroenterology 1995;109:2043-
2046. 284. Lee WM. Acute Liver Failure in Current Practice of Medicine,
Gastroenterology/Hepatology volume, Willis C. Maddrey, editor, Current Medicine, Philadelphia, 1996, pp. 5.1-5.7.
285. Lee WM. Medical management of acute liver failure. In Lee WM and
Williams R, Eds. Acute Liver Failure. Cambridge University Press, Cambridge UK, 1997, pp. 115-131.
286. Lee WM and Williams R, Eds. Acute Liver Failure. Cambridge University
Press, Cambridge UK, 1997. 300 page text. 287. Lee WM. Editorial: Prostaglandins for clinical use: Are we there yet? Liver
Transplant Surg 1996;2:240-241. 288. Lee WM, Sorrell MF. Editorial. Developing a world view toward acute liver
failure.. Hepatology 1996;24:270-71. 289. Lee WM. Specific hepatitis C virus NS5A sequences determine the
outcome of interferon treatment. Gastroenterology 111:1152-1154,1996. 290. Lee WM. Management of acute liver failure. Semin Liver Dis 1996;16:369-
78,. 291. Schiødt FV, Jain R, Lee WM. Gastroenterology chapter in Critical Care
Pearls 1997, 2nd edition, S Sahn, J Heffner, eds. Hanley and Belfus Inc. Philadelphia.
292. Lee WM. Drug-induced liver injury. IM-Internal Medicine July 1997, pp. 19-
32. 293. Peterson WL, Lee WM. Contempo: Gastroenterology and Hepatology
(Review of year’s literature) JAMA 277:1858-60, 1997. 294. Lee WM. Therapy of chronic hepatitis C: Interferon alpha 2a trials. NIH
Consensus Development Conference Proceedings. Hepatology 26;89S-95S, 1997.
Lee WM CV, p. 36
295. Hamid SV, Lee WM. Pregnancy and Chronic Liver Disease in Gleicher N, ed. Principles and Practice of Medical Therapy in Pregnancy. p., Appleton and Lange Co. East Norwalk. Third Edition, 1998.
296. Lee WM. Acute Liver Failure in Current Practice of Medicine,
Gastroenterology/Hepatology volume, Willis C. Maddrey, editor, Current Medicine, Philadelphia, 2nd edition, 1998.
297. Mabee CL, Crippin JS, Lee WM. Review article: interferon and hepatitis C:
factors predicting therapeutic outcome. Aliment Pharm Therapeut 1998; 12: 509-518.
298. Lee WM, Schiødt FV. Fulminant Hepatic Failure in Schiff’s Diseases of the
Liver, Eighth edition. Schiff ER, Sorrell, MF, Maddrey WC, editors, Lippincott-Raven Publishers, Philadelphia, 1998.
299. Hamid S. Cruz PD Jr. Lee WM. Urticarial vasculitis caused by hepatitis C
virus infection: response to interferon alfa therapy J Am Acad Dermatol 1998;39:278-80.
300. Lee WM. The case for case reports: Editorial. Ital J Gastroenterol 30:318-
19, 1998. 301. FV Schiødt, Lee WM. Management of acetaminophen toxicity in Medical
Management of Liver Disease, Edward L. Krawitt, Editor, Marcel Dekker, New York, 1999.
302. Lee WM, Ed. Hepatitis B, volume 3, no. 2 in series, Clinics in Liver
Disease, Philadelphia, WB Saunders and Co., 432 pp., 1999. 303. Malik AH, Lee WM. Hepatitis B therapy: the plot thickens. Editorial.
Hepatology 1999;30: 579-581. 304. Morales CP, Saboorian MH, Miller GL, Lee WM. Adrenal gland sampling
during transjugular liver biopsy leads to misdiagnosis of hepatocellular carcinoma. Amer J Gastroenterol 1999;94:3071-2.
305. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam
NT, Wisecarver JL, Rabkin JM, Lee WM, the Acute Liver Failure Study Group. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transplant Surg 1999;5:480-484.
Lee WM CV, p. 37
306. Malik AH, Lee WM. Review article: Chronic hepatitis B virus infection: Treatment strategies for the next millennium. Ann Intern Med 2000;132:723-731.
307. Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, Freise
C, Lee WM, Bass NM, the Acute Liver Failure Study Group. Troglitazone induced fulminant hepatic failure: a report of three cases. Dig Dis Sci 2000;45;549-553.
308. Ostapowicz G, Lee WM. Acute Liver Failure: the Western experience. J
Gastroenterol Hepatol 2000;15:480-88. 309. Ostapowicz G, Lee WM. Acute liver failure in Gastroenterology and
Hepatology: The Comprehensive Visual Reference. Vol 1. The Liver eds. Feldman M, Maddrey WC. Current Medicine, Philadelphia, 2000, pp. 7.1-7.16..
310. Lee WM. Assessing causality in drug-induced liver injury: Editorial. J
Hepatol 2000;33:338-40. 311. Kumar KS, Lee WM. Chylous ascites with marked elevation of CA-125 in
cirrhosis. Am J Gastroenterol 2000;95;3313-4. 312. Lee WM. Acute Liver Failure in Clinical Perspectives in Gastroenterology,
AGA, March-April, 2001,101-110. 313. Malik AH, Collins Jr RH, Saboorian MH, Lee WM. Chronic graft-versus-
host disease after hematopoietic cell transplantation presenting as an acute hepatitis. Am J Gastroenterol 2001:96:588-590.
314. Kumar KS, Saboorian MH, Lee WM. Cholestatic presentation of chronic
hepatitis C: a clinical and histological study with a review of the literature. Dig Dis Sci 2001;46:2066-73.
315. Schiødt FV, Lee WM. Liver transplantation for acute liver failure: better
safe than sorry. Liver Transplant 2002;8:1063-4. 316. Ostapowicz GA, Lee WM. Management of acetaminophen toxicity. In
Drug-Induced Liver Disease, Eds. Deleve L, Kaplowitz N, 2002; pp.327-44. 317. Ocama P, Lee WM. Don’t Forget This Infectious Killer. The New York
Times, March 1, 2003. Op Ed page article. 318. Schiodt FV, Lee WM. Fulminant liver disease. Clin Liv Dis 2003;7:331-49.
Lee WM CV, p. 38
319. Schiødt FV and Lee WM. Drug-induced liver injury. In Yamada Atlas of
Gastroenterology and Hepatology, Philadelphia, PA; Third Edition, pp. 637-40, 2003.
320. Schiødt FV and Lee WM. Drug-induced liver disease. In Yamada
Textbook of Gastroenterology and Hepatology, Fourth Edition, Philadelphia, PA; pp. 2352-66, 2003.
321. Vaquero J, Jordano Q, Lee WM, Blei AT and the Acute Liver Failure Study
Group. Serum S-100b in acute liver failure. Results of the US Acute Liver Failure Study Group. Liver Transplant 2003;9:887-8.
322. Lee WM. Acute liver failure in the United States. Semin Liv Dis 2003,
23:217-26. 323. Polson J, Lee WM. Acute liver failure in Gastroenterology and Hepatology:
The Comprehensive Visual Reference. Vol 1. The Liver eds. Feldman M, Maddrey WC. Current Medicine, Philadelphia, 2003, p. 7.1-7.16.
324. Polson J, Lee WM. Acute liver failure in Atlas of the Liver. Third edition,
Maddrey WC, Feldman M. Current Medicine, Philadelphia, 2003, p. 173-185. 325. Lee WM, and Schiødt FV. Toxic and drug-induced liver disease. Chapter
in Cecil’s Textbook of Medicine, Goldman L, Ausiello D, Eds. Saunders, Philadelphia, PA, 2004: pp. 906-11.
326. Ocama P and Lee WM. Cirrhosis in Conn’s Current Therapy, 2004
Edition. Rakel RE, Bope ET, Eds. Saunders, Philadelphia, PA, pp. 513-20. 327. Lee WM. Aches, pains and warning labels. Op Ed piece in The New York
Times, March 17, 2004. 328. Lee WM. Sounding Board: Acetaminophen Hepatotoxicity and the U.S.
Acute Liver Failure Study: Lowering the Risks of Hepatic Failure. Hepatology, 2004;40:6-9.
329. Polson J, Lee WM. Analyzing liver transplantation for fulminant hepatic
failure at UCLA. Commentary in Liver Transplantation Worldwide. Liver Transplantation 2004;10:953-4.
330. Lee WM, Senior JR. Recognizing drug-induced liver injury: current
problems, possible solutions. Toxicol Pathol 2005;33:155-64.
Lee WM CV, p. 39
331. Lee WM. Current view of drug hepatotoxicity from across the pond. Eur J Hosp Pharm 2005;11:61-62.
332. Yuan H-J, Lee WM. Molecular mechanisms of resistance to antiviral
therapy in patients with chronic hepatitis B. Molecular Medicine 2007:7:185-197.
333. Ostapowicz GA, Lee WM. Acetaminophen: Pathology and clinical
presentation of hepatotoxicity. In Drug-Induced Liver Disease, Eds. Deleve L, Kaplowitz N, 2007; pp.389-406.
334. Lee WM. Acetaminophen hepatotoxicity: Changing perceptions of a
social/medical issue. Hepatology, 2007, 46:966-70. 335. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I: Hepatocellular
injury, in Drug-Induced Liver Disease, September 2007 issue of Clinics in Liver Disease, WM Lee, Guest Editor, Philadelphia PA.
336. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy II: Atypical hepatic
injuries, in Drug-Induced Liver Disease, September 2007 issue of Clinics in Liver Disease, WM Lee, Guest Editor, Philadelphia PA.
337. Polson J, Lee WM. Editorial: Etiologies of acute liver failure: location,
location, location! Liver Transplant 2007;13:1364-5. 338. Lee WM. Management of drug-induced acute liver failure. Chapter in
Hepatotoxicity. 2007, International Hepatology Updates, Permanyer Publications, Barcelona, pp. 137-146.
339. Yuan H-J, Lee WM. Non-response to treatment for hepatitis C: Current
Management Strategies. Drugs, 2008;68:27-42. 340. Seremba E and Lee WM. Drug-induced liver disease. In Yamada
Textbook of Gastroenterology and Hepatology, Fifth Edition, Philadelphia, PA, 2008.
341. Schiødt FV and Lee WM. Drug-induced liver injury. In Yamada Atlas of
Gastroenterology and Hepatology, Philadelphia, PA; Fourth Edition, pp. 637-40, 2008.
342. Lee WM. Acetaminophen-related acute liver failure in the United States.
Hepatology Res 2008, 38 (Suppl. 1): S3–S8
Lee WM CV, p. 40
343. Naderi ASA, Farsian NF, Lee WM. Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. Eur J Gastroenterol Hepatol 2008;20:1115-1117.
344. Lee WM, Seremba E. Etiologies of acute liver failure. Curr Opin Crit Care
2008:14:198-201. 345. Lee WM. Liver failure and liver support. Semin Liver Dis 2008;28:135-6. 346. Lee WM, Wijdicks E. Acute liver failure and cerebral edema: When the
hepatologist meets the neurointensivist. Neuro Crit Care 2008;9:1-2. 347. Stravitz RT, Lee WM, Kramer AH, Kramer DJ, Hynan L, Blei AT.
Therapeutic hypothermia for acute liver failure: Toward a randomized, controlled trial in patients with advanced hepatic encephalopathy. Neurocrit Care 2008;9:90-96.
348. Munoz SJ, Reddy KR, Lee WM and the Acute Liver Failure Study Group.
The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008;9:103-107.
349. Lee WM, Jalan RV. Treatment of hyperammonemia in liver failure: A tale
of two enzymes. Gastroenterology 2009;136:2048-51. 350. Lee WM, Larson AM, Arenas J. Thinking through acetaminophen toxicity
and transplantation: choosing worthy recipients. Liver Transpl 2009;15:567-569.
351. Lee WM. Point-counterpoint: The case for limiting acetaminophen-related
deaths: Smaller doses and unbundling the opioid-acetaminophen compounds. Clin Pharm Therap 2010;88:289-92.
352. Lee WM. Commentary: Persistently increased acetaminophen
concentrations in a patient with acute liver failure. Clin Chem 2011;57:12-13. 353. Yuan HJ, Lee WM. Editorial: Update of Chronic Hepatitis B. Current
Opinion in Gastroenterology 2011;27:217-23. 354. Tujios S, Lee WM. Acute Liver Failure in Sherlock’s Diseases of the Liver
and Biliary System, 12th edition, edited by Dooley J, Burroughs A, Heathcote J and Lok ASF. London, 2011.
Lee WM CV, p. 41
355. Lee WM. Drug-induced liver disease. In Yamada Textbook of Gastroenterology and Hepatology, Sixth Edition, Philadelphia, PA, In press, 2011.
356. Hanje AJ, Michaels A, Lee WM. Is N-acetylcysteine Effective in All Non-
acetaminophen Acute Liver Failure. In Controversies in Hepatology. Donald M. Jensen, Editor. Slack Incorporated, Philadelphia, 2011.
357. Lee WM. Toxin- and Drug-Induced Liver Disease. In Cecil’s Textbook of Medicine, 24th Edition, Lee Goldman, Editor, 2011, p.
358. Lee WM. Determining prognosis in acute liver failure. Nat Rev
Gastroenterol Hepatol 2012;9:192-4. 359. Lee WM. Acute Liver Failure. Semin Respir Crit Care Med. 2012;33:36-45. 360. Tujios SR, Lee WM. New advances in chronic hepatitis B. Curr Opin
Gastroenterol 2012;28:193-97. 361. Casey LC, Lee WM. Hepatitis C therapy update.
Curr Opin Gastroenterol 2012;28:188-92. 362. Lee WM. Recent developments in acute liver failure. Clin Gastroenterol
2012; 26:3-16.
363. Almadani B, Sood N, Yearsley M, Lee WM. Life threatening variceal hemorrhage in a woman with severe pulmonary arterial hypertension. Gastroenterol and Hepatol 2012;8:404-408.
364. Lee WM. Acute liver failure. Semin Respir Crit Care Med 2012;33:36-45. 365. Lee WM. Liver: determining prognosis in acute liver failure. Nat Rev
Gastroenterol Hepatol 2012;9:192-4. 366. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American
Association for the Study of Liver Diseases Position Paper on acute liver failure. Hepatology 2012;55:965-7.
367. Casey LC, Lee WM. Hepatitis C therapy update 2013. Curr Opin
Gastroenterol. 2013;29:243-9. 368. Tujios SR, Lee WM. Update in the management of chronic hepatitis B.
Curr Opin Gastroenterol 2013;29:250-6.
Lee WM CV, p. 42
369. Tran Thanh, Lee WM. DILI: New insights into diagnosis and management. Curr Hep Rep 2013: epub ahead of print.
370. Lee WM. Drug-induced liver injury. Clin Liver Dis 2013;17;575–586. 371. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana
RJ. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-66
372. Apica BS and Lee WM. Drug-Induced Liver Injury. In: Linda M. McManus,
Richard N. Mitchell, editors. Pathobiology of Human Disease. San Diego: Elsevier; 2014. p. 1825-1837.
373. Bernal W, Lee WM, Wendon J, Larsen FS, Williams R. Acute liver failure: A curable disease by 2024? J Hepatol 2015 ;62(1 Suppl):S112-20
374. Lee WM and Dienstag J. Toxic and Drug-Induced Hepatitis. In: Kasper
DL, Fauci A, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s 19th Edition, Principles of Internal Medicine, McGraw Hill, New York: 2015; p. 2023-30.
375. Lee WM. Toxic and Drug-Induced Liver Disease. In: Goldman L and
Schafer AI. Goldman-Cecil Medicine, 25th Edition, 2015, Elsevier, Philadelphia PA, p. 1006-1010.
376. Lee WM. Drug-Induced Liver Disease. Chapter 97, pp 1958-72. In:
Podolsky D, et al. Yamada’s Textbook of Gastroenterology, 6th Edition, 2015; Hoboken, NJ.
377. Lee WM. Acute Liver Failure. Chapter 98, pp 1973-88. In: Podolsky D, et
al. Yamada’s Textbook of Gastroenterology, 6th Edition, 2015; Hoboken, NJ.
378. Thanh T, Lee WM. Drug-Induced Liver Disease in Scientific American Gastroenterology, Hepatology, and Endoscopy, electronic book. New York 2016.
367. Thanh T, Burrell M, Lee WM. Hepatic arterio-portal fistulae: Two case reports and a review of the literature. Clin Med Rev Case Rep 2015;2:3.
